HomeVLA • EPA
add
Valneva SE
Previous close
€3.19
Day range
€3.20 - €3.38
Year range
€2.95 - €7.24
Market cap
458.08M EUR
Avg Volume
588.94K
P/E ratio
-
Dividend yield
-
Primary exchange
EPA
In the news
Financials
Income Statement
Revenue
Net income
(EUR) | Mar 2024info | Y/Y change |
---|---|---|
Revenue | 32.75M | -2.25% |
Operating expense | -70.75M | -555.37% |
Net income | 58.91M | 424.98% |
Net profit margin | 179.86 | 432.46% |
Earnings per share | 0.88 | 407.50% |
EBITDA | 71.15M | 675.02% |
Effective tax rate | 0.01% | — |
Balance Sheet
Total assets
Total liabilities
(EUR) | Mar 2024info | Y/Y change |
---|---|---|
Cash and short-term investments | 176.64M | -30.59% |
Total assets | 502.83M | -14.77% |
Total liabilities | 313.60M | -18.59% |
Total equity | 189.23M | — |
Shares outstanding | 140.26M | — |
Price to book | 2.36 | — |
Return on assets | 35.42% | — |
Return on capital | 46.21% | — |
Cash Flow
Net change in cash
(EUR) | Mar 2024info | Y/Y change |
---|---|---|
Net income | 58.91M | 424.98% |
Cash from operations | -28.43M | -16.88% |
Cash from investing | 86.71M | 2,535.07% |
Cash from financing | -7.46M | -95.41% |
Net change in cash | 50.56M | 257.77% |
Free cash flow | 19.93M | 158.46% |
About
Valneva SE is a French biotech company headquartered in Saint-Herblain, France, developing and commercializing vaccines for infectious diseases. It has manufacturing sites in Livingston, Scotland; Solna, Sweden, and Vienna, Austria; with other offices in France, Canada and the United States. Wikipedia
Founded
2013
Website
Employees
676